Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ria

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
The Journal of Pathology|December 17, 2021
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAsIlaria Saltarella, Aurelia Lamanuzzi, Vanessa Desantis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myelomaMichele Moschetta, Antonio Basile, Arianna Ferrucci, et al.
Frontiers in Medicine|June 2, 2022
Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, <i>ex vivo</i> and <i>in vitro</i> AnalysisSebastiano Cicco, Vanessa Desantis, Antonio Vacca, et al.
Blood|May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialAntonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
The Journal of Pathology|August 1, 2012
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patientsAntonio Basile, Michele Moschetta, Paolo Ditonno, et al.
Haematologica|November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersFrancesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic targetRoberto Ria, Ivana Catacchio, Simona Berardi, et al.
Neoplasia (New York, N.Y.)|December 12, 2018
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?Ilaria Saltarella, Maria Antonia Frassanito, Aurelia Lamanuzzi, et al.
Frontiers in Medicine|February 8, 2021
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency DepartmentAntonio Giovanni Solimando, Nicola Susca, Paola Borrelli, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
The Journal of Pathology|December 17, 2021
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAsIlaria Saltarella, Aurelia Lamanuzzi, Vanessa Desantis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myelomaMichele Moschetta, Antonio Basile, Arianna Ferrucci, et al.
Frontiers in Medicine|June 2, 2022
Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, <i>ex vivo</i> and <i>in vitro</i> AnalysisSebastiano Cicco, Vanessa Desantis, Antonio Vacca, et al.
Blood|May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialAntonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
The Journal of Pathology|August 1, 2012
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patientsAntonio Basile, Michele Moschetta, Paolo Ditonno, et al.
Haematologica|November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersFrancesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic targetRoberto Ria, Ivana Catacchio, Simona Berardi, et al.
Neoplasia (New York, N.Y.)|December 12, 2018
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?Ilaria Saltarella, Maria Antonia Frassanito, Aurelia Lamanuzzi, et al.
Frontiers in Medicine|February 8, 2021
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency DepartmentAntonio Giovanni Solimando, Nicola Susca, Paola Borrelli, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Pageof 14